These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29209847)

  • 41. Venous thromboembolism in patients with diffuse large B-cell lymphoma.
    Komrokji RS; Uppal NP; Khorana AA; Lyman GH; Kaplan KL; Fisher RI; Francis CW
    Leuk Lymphoma; 2006 Jun; 47(6):1029-33. PubMed ID: 16840193
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma.
    Sanfilippo KM; Carson KR; Wang TF; Luo S; Edwin N; Kuderer N; Keller JM; Gage BF
    Res Pract Thromb Haemost; 2022 Jan; 6(1):e12634. PubMed ID: 35028491
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: results from a prospective cohort study with Asian population.
    Park LC; Woo SY; Kim S; Jeon H; Ko YH; Kim SJ; Kim WS
    Thromb Res; 2012 Sep; 130(3):e6-12. PubMed ID: 22507288
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased risk of venous thromboembolism in patients with bullous pemphigoid. The INVENTEP (INcidence of VENous ThromboEmbolism in bullous Pemphigoid) study.
    Cugno M; Marzano AV; Bucciarelli P; Balice Y; Cianchini G; Quaglino P; Calzavara Pinton P; Caproni M; Alaibac M; De Simone C; Patrizi A; Cozzani E; Papini M; Tedeschi A; Berti E; Rosendaal FR;
    Thromb Haemost; 2016 Jan; 115(1):193-9. PubMed ID: 26245987
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk Assessment for Venous Thromboembolism in Chemotherapy-Treated Ambulatory Cancer Patients.
    Ferroni P; Zanzotto FM; Scarpato N; Riondino S; Nanni U; Roselli M; Guadagni F
    Med Decis Making; 2017 Feb; 37(2):234-242. PubMed ID: 27491558
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.
    Kashanian SM; Holtzman NG; Patzke CL; Cornu J; Duffy A; Koka M; Niyongere S; Duong VH; Baer MR; Apata J; Kamangar F; Emadi A
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):817-826. PubMed ID: 33677674
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
    Shin HC; Seo J; Kang BW; Moon JH; Chae YS; Lee SJ; Lee YJ; Han S; Seo SK; Kim JG; Sohn SK; Park TI
    Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chronological pattern of venous thromboembolism (VTE) occurrence impacts in survival of pancreatic ductal adenocarcinoma (PDAC).
    González Caraballo I; Martín Lozano R; Jiménez Rodríguez R; Soto Alsar J; Ortega Morán L; Martín Jiménez M; Muñoz Martín AJ
    Clin Transl Oncol; 2024 Sep; 26(9):2388-2392. PubMed ID: 38558283
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of venous thromboembolism in patients treated for bacterial infection in the community with outpatient parenteral antimicrobial therapy.
    Barr DA; Irvine S; Ritchie ND; McCutcheon J; Seaton RA
    QJM; 2014 Mar; 107(3):207-11. PubMed ID: 24300160
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer.
    Piver RN; Wagner VM; Levine MD; Backes FJ; Chambers LJ; Cohn DE; Copeland LJ; Cosgrove CM; Nagel CI; O'Malley DM; Bixel KL
    Gynecol Oncol Rep; 2023 Apr; 46():101156. PubMed ID: 36910448
    [TBL] [Abstract][Full Text] [Related]  

  • 51. VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients.
    Ferroni P; Palmirotta R; Riondino S; De Marchis ML; Nardecchia A; Formica V; Guadagni F; Roselli M
    Thromb Haemost; 2016 Jan; 115(1):143-51. PubMed ID: 26336029
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
    Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
    Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Validation of the Khorana Score for Prediction of Venous Thromboembolism After Robot-Assisted Radical Cystectomy.
    Iqbal U; Elsayed AS; Ozair S; Jing Z; James G; Li Q; Hussein AA; Guru KA
    J Endourol; 2021 Jun; 35(6):821-827. PubMed ID: 33218263
    [No Abstract]   [Full Text] [Related]  

  • 54. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
    PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Time to Event Analysis for the Development of Venous Thromboembolism After Spinal Fusion ≥ 5 Levels.
    McClendon J; Smith TR; O'Shaughnessy BA; Sugrue PA; Thompson SE; Koski TR
    World Neurosurg; 2015 Sep; 84(3):826-33. PubMed ID: 25871780
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
    Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison among three predictive models for cancer-associated thromboembolism in a hispanic population.
    Ramos-Esquivel A; Marenco-Flores A; Hernández-Romero G; Céspedes-Calvo A; Mora-Hidalgo R
    J Thromb Thrombolysis; 2023 Oct; 56(3):433-438. PubMed ID: 37407771
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy.
    Yuen HLA; Slocombe A; Heron V; Chunilal S; Shortt J; Tatarczuch M; Grigoriadis G; Patil S; Gregory GP; Opat S; Gilbertson M
    Res Pract Thromb Haemost; 2020 Aug; 4(6):997-1003. PubMed ID: 32864550
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incidence of Venous Thromboembolism in cancer patients treated with Cisplatin based chemotherapy - a cohort study.
    Zahir MN; Shaikh Q; Shabbir-Moosajee M; Jabbar AA
    BMC Cancer; 2017 Jan; 17(1):57. PubMed ID: 28093087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.